Perez 2010.

Methods	Study design: active comparator, open‐label, parallel RCT Duration of study: not reported Duration of follow‐up: 12 months
Participants	Country: Spain Setting: single centre Inclusion criteria: kidney transplant recipients with stable kidney function Number: treatment group (31); control group (21) Mean age, range (years): treatment group (60, 53 to 65); control group (55, 42 to 61) Sex (M/F): treatment group (26/5); control group (17/4) Exclusion criteria: not reported
Interventions	Treatment group Paricalcitol (oral): 1µg/d Control group No treatment Co‐interventions Not reported
Outcomes	Change in BMD at lumbar spine and femoral neck Change in PTH, serum calcium, phosphate, alkaline phosphatase Kidney function (eGFR and SCr)
Notes	Funding source: not reported Trial registration: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Not blinded. Patients allocated to oral treatment or no treatment
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	High risk	Patient important outcomes not captured or reported systematically
Other bias	Low risk	No additional threats to validity identified